DDInter1628 DDInter1715
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant activation of the JAK-STAT pathway, leading to abnormal blood cell counts and thrombotic complications. By inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and prevents abnormal blood cell proliferation. Due to a large number of patients with myeloproliferative neoplasms who have JAK2 mutations, ruxolitinib was the first ATP-competitive inhibitor of JAK1 and JAK2 ever developed. Rux
Strontium chloride (Sr-89), initially FDA-approved in 1993, is used as a paliative therapeutic option to help relieve the pain from bone metastases. Strontium chloride is mainly used in cases of metastatic castrate-resistant prostate cancer. Bone metastases is a common and severe complication presented in advanced stages of the disease. It is usually presented mainly in patients with prostatic and breast cancer, as well as in cancer of lung, bladder and thyroid. There has been some cases of apparent tumor regression which has given it a potential tumoricidal effect.
Ruxolitinib {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Carmustine
Carmustine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Strontium chloride Sr-89
Ruxolitinib {u} (Compound) causes {v} (Side Effect) Urinary tract infection
Urinary tract infection {u} (Side Effect) is caused by {v} (Compound) Carmustine
Carmustine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Strontium chloride Sr-89
Ruxolitinib {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Chloramphenicol
Chloramphenicol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Strontium chloride Sr-89
Ruxolitinib {u} (Compound) binds {v} (Gene) PHKG2
PHKG2 {u} (Gene) is upregulated by {v} (Compound) Chloramphenicol
Chloramphenicol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Strontium chloride Sr-89
Ruxolitinib {u} (Compound) causes {v} (Side Effect) Urinary tract infection
Urinary tract infection {u} (Side Effect) is caused by {v} (Compound) Cladribine
Cladribine {u} may lead to a major life threatening interaction when taken with {v} Strontium chloride Sr-89
Ruxolitinib {u} (Compound) downregulates {v} (Gene) OSBPL10
OSBPL10 {u} (Gene) is downregulated by {v} (Compound) Zidovudine
Zidovudine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Strontium chloride Sr-89
Ruxolitinib {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Cladribine
Cladribine {u} may lead to a major life threatening interaction when taken with {v} Strontium chloride Sr-89
Ruxolitinib {u} (Compound) downregulates {v} (Gene) POLB
POLB {u} (Gene) is bound by {v} (Compound) Cytarabine
Cytarabine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Strontium chloride Sr-89
Ruxolitinib {u} (Compound) upregulates {v} (Gene) PTGS2
PTGS2 {u} (Gene) is upregulated by {v} (Compound) Cytarabine
Cytarabine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Strontium chloride Sr-89
Ruxolitinib {u} (Compound) downregulates {v} (Gene) BRCA1
BRCA1 {u} (Gene) is upregulated by {v} (Compound) Cytarabine
Cytarabine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Strontium chloride Sr-89
Ruxolitinib (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Carmustine (Compound) and Carmustine may cause a moderate interaction that could exacerbate diseases when taken with Strontium chloride Sr-89
Ruxolitinib (Compound) causes Urinary tract infection (Side Effect) and Urinary tract infection (Side Effect) is caused by Carmustine (Compound) and Carmustine may cause a moderate interaction that could exacerbate diseases when taken with Strontium chloride Sr-89
Ruxolitinib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Chloramphenicol (Compound) and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Strontium chloride Sr-89
Ruxolitinib (Compound) binds PHKG2 (Gene) and PHKG2 (Gene) is upregulated by Chloramphenicol (Compound) and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Strontium chloride Sr-89
Ruxolitinib (Compound) causes Urinary tract infection (Side Effect) and Urinary tract infection (Side Effect) is caused by Cladribine (Compound) and Cladribine may lead to a major life threatening interaction when taken with Strontium chloride Sr-89
Ruxolitinib (Compound) downregulates OSBPL10 (Gene) and OSBPL10 (Gene) is downregulated by Zidovudine (Compound) and Zidovudine may cause a moderate interaction that could exacerbate diseases when taken with Strontium chloride Sr-89
Ruxolitinib (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Cladribine (Compound) and Cladribine may lead to a major life threatening interaction when taken with Strontium chloride Sr-89
Ruxolitinib (Compound) downregulates POLB (Gene) and POLB (Gene) is bound by Cytarabine (Compound) and Cytarabine may cause a moderate interaction that could exacerbate diseases when taken with Strontium chloride Sr-89
Ruxolitinib (Compound) upregulates PTGS2 (Gene) and PTGS2 (Gene) is upregulated by Cytarabine (Compound) and Cytarabine may cause a moderate interaction that could exacerbate diseases when taken with Strontium chloride Sr-89
Ruxolitinib (Compound) downregulates BRCA1 (Gene) and BRCA1 (Gene) is upregulated by Cytarabine (Compound) and Cytarabine may cause a moderate interaction that could exacerbate diseases when taken with Strontium chloride Sr-89